Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Publication of Preclinical and Early Clinical Data Demonstrating Best-in-Class, Pan-Mutant Activity of BTK Inhibitor Docirbrutinib

FY2026 Q1 Presentation

Consolidated Financial Results for the First Quarter of the Year Ending December 31, 2026

Carna to Present Preclinical Findings on Monzosertib‑Induced Cancer Cell Death at AACR Annual Meeting

Corporate Presentation Feb. 2026

FY2025 Presentation

Consolidated Financial Results for the Year Ended December 31, 2025

Updates from the ongoing Phase 1b study and new preclinical findings of the next-generation BTK inhibitor, docirbrutinib (AS-1763), presented at the 67th American Society of Hematology Annual Meeting